Does Blue Cross Blue Shield Cover Vardenafil (Levitra/Staxyn)?

BCBS Formulary Placement for Vardenafil

Generic vardenafil typically sits on Tier 2 (preferred brand) or Tier 3 (non-preferred) across most Blue Cross Blue Shield commercial PPO and HMO formularies. The FDA approved vardenafil (as Levitra) in 2003 for erectile dysfunction based on key trials demonstrating significant efficacy over placebo 1. Since generic vardenafil became available in 2018, most BCBS affiliates shifted brand Levitra to non-preferred or excluded status.

Formulary tier determines your copay. A Tier 2 generic vardenafil prescription typically costs $15-$40 per fill, while Tier 3 placement may mean $50-$80. Brand Levitra, if covered at all, often requires Tier 4 copays exceeding $100 per fill. The FDA-approved prescribing information lists standard dosing at 10 mg taken approximately 60 minutes before sexual activity, with adjustment to 5 mg or 20 mg based on efficacy and tolerability. BCBS quantity limits commonly restrict dispensing to 6-12 tablets per 30-day period, consistent with the labeled recommendation of once-daily maximum dosing 2.

Each BCBS state affiliate maintains its own formulary committee. Blue Cross Blue Shield of Texas may tier vardenafil differently than BCBS of Massachusetts. The Federal Employee Program (FEP), which covers approximately 5.3 million federal employees and dependents, maintains a separate national formulary that generally includes generic vardenafil with quantity limits. Checking your specific Summary of Benefits and Coverage document is the only way to confirm your exact tier placement.

Prior Authorization Requirements

Approximately 40-60% of BCBS state plans require prior authorization for at least one formulation of vardenafil. Prior authorization for ED medications typically requires documentation of an erectile dysfunction diagnosis plus one or more of the following: clinical assessment confirming ED, relevant comorbidity evaluation, or documented cardiovascular safety 3.

The prior authorization process usually requires your prescriber to submit a form confirming the diagnosis of erectile dysfunction (ICD-10 code N52.01 through N52.9), documentation that the medication is not being prescribed for a cosmetic or non-medical purpose, and confirmation of cardiovascular safety. The American Urological Association guidelines recommend PDE5 inhibitors as first-line pharmacotherapy for ED 4, which supports medical necessity arguments during prior authorization. According to a 2018 AUA guideline update, "PDE5 inhibitors should be offered as first-line therapy to men with ED who desire treatment" 4.

Your prescriber can typically complete prior authorization within 24-72 hours for standard requests. Urgent requests (defined as situations where delay could seriously jeopardize health) must receive a decision within 24 hours under most state insurance regulations. If your physician's office submits incomplete documentation, expect delays. Common reasons for PA denial include missing diagnostic codes, failure to document that the medication treats an FDA-approved indication, or exceeding quantity limits.

Step Therapy Protocols at BCBS

Many BCBS plans impose step therapy requiring a trial of sildenafil (generic Viagra) before approving vardenafil. This reflects cost containment strategy, as generic sildenafil typically costs $3-$15 per tablet versus $5-$25 for generic vardenafil. Step therapy protocols usually require documentation of a 30-day trial of sildenafil with either inadequate efficacy or intolerable side effects 5.

Clinical evidence supports that patients who fail one PDE5 inhibitor may respond to another. A crossover study by Carson et al. found that 62% of sildenafil non-responders achieved successful intercourse with vardenafil 6. The pharmacologic basis for this is clear: vardenafil has approximately 10-fold greater potency for PDE5 inhibition than sildenafil in vitro, though clinical dose adjustments normalize this difference 7. Porst et al. demonstrated in a fixed-dose study (N=580) that vardenafil 20 mg produced successful intercourse in 75% of attempts versus 30% for placebo 1.

To bypass step therapy, your prescriber can submit a step therapy exception request documenting: prior sildenafil trial with dates, reason for failure (lack of efficacy, adverse effects such as visual disturbances, headache, or flushing), or a clinical contraindication to sildenafil (such as concurrent use of a medication that contraindicates sildenafil specifically). Some BCBS plans also waive step therapy if the patient has a documented intolerance or allergy.

How to Appeal a BCBS Denial for Vardenafil

If BCBS denies coverage for vardenafil, you have the right to appeal through a structured process. The typical BCBS appeal pathway follows three levels: internal appeal to the plan, second-level internal review, and external review by an independent review organization (IRO).

For the first-level internal appeal, submit within 180 days of the denial. Include your prescriber's letter of medical necessity, relevant clinical documentation (office notes confirming ED diagnosis, any prior medication trials), and supporting guideline citations. The AUA guidelines explicitly state that PDE5 inhibitors are first-line ED therapy 4, and the Endocrine Society clinical practice guideline on testosterone therapy also addresses ED treatment algorithms 8.

Second-level appeals should include additional clinical evidence not presented in the first appeal. Consider adding peer-reviewed literature demonstrating vardenafil's specific advantages for your clinical situation. For patients with diabetes-related ED, Goldstein et al. demonstrated that vardenafil significantly improved erectile function in diabetic men (IIEF-EF domain improvement of 5.9 points vs. 1.4 for placebo, P<0.001) 9. For patients on antihypertensives, vardenafil's minimal blood pressure interaction profile may constitute clinical justification 10.

External review represents your final option. According to federal data compiled from state insurance departments, external reviews overturn approximately 40-54% of medical necessity denials for prescription medications. Your state insurance commissioner's office can provide specific external review filing instructions.

Staxyn (Vardenafil ODT) Coverage Specifics

Staxyn, the orally disintegrating tablet formulation of vardenafil, faces more restrictive coverage than standard vardenafil tablets. Most BCBS plans either exclude Staxyn entirely or place it on Tier 4 (specialty) with significant cost-sharing requirements. The ODT formulation delivers 10 mg vardenafil without water, which provides a convenience advantage but no pharmacokinetic superiority over the standard tablet 11.

For patients who genuinely need the ODT formulation (difficulty swallowing tablets due to neurological conditions, head and neck surgery, or esophageal disorders), prior authorization requests should clearly document the swallowing impairment. A supporting letter from a gastroenterologist or neurologist strengthens these requests. The bioavailability of Staxyn differs from Levitra tablets. Staxyn should not be substituted on a mg-for-mg basis with Levitra, and the two formulations are not interchangeable per FDA labeling 2.

BCBS Federal Employee Program (FEP) Coverage

The BCBS Federal Employee Program covers approximately 5.3 million enrollees and operates under a national formulary distinct from state-level BCBS plans. FEP Basic and Standard options typically include generic vardenafil with quantity limits of 6 tablets per 30-day supply. The FEP formulary is updated quarterly, and changes are published in the FEP Brochure available through the Office of Personnel Management 12.

FEP prior authorization criteria for ED medications generally mirror those of commercial BCBS plans but apply uniformly across all states. FEP also uses a mail-order pharmacy benefit that can reduce cost-sharing for vardenafil. A 90-day supply through FEP mail order typically costs 2x the retail copay rather than 3x, offering meaningful savings for maintenance ED therapy.

FEP appeals follow a distinct process from state BCBS plans. The FEP Director's Office handles second-level appeals, and external review is conducted through the Office of Personnel Management rather than state insurance departments. Response timelines are federally mandated: 30 days for standard pre-service appeals, 72 hours for urgent appeals.

Cost Optimization Strategies

Even with BCBS coverage, several strategies can reduce your out-of-pocket costs for vardenafil. Generic vardenafil 20 mg tablets can be split to yield two 10 mg doses, effectively halving per-dose cost. The FDA notes that scored tablets can be safely split, though vardenafil tablets are film-coated and not scored, so discuss this with your pharmacist 13.

Manufacturer copay assistance programs may be combined with commercial BCBS coverage in most states. Bayer (Levitra's original manufacturer) and current generic manufacturers periodically offer copay cards reducing cost to $0-$30 per fill. These programs cannot be used with government-funded insurance (Medicare, Medicaid, TRICARE, or VA) per federal anti-kickback statute requirements, but they work with commercial BCBS plans 14.

Comparing pharmacy pricing within your BCBS network can yield substantial savings. Cost differences of 300-400% for identical generic vardenafil between in-network pharmacies are common. Preferred pharmacies in your BCBS network typically offer the lowest cost-sharing. The average wholesale price (AWP) for generic vardenafil 20 mg is approximately $8-$12 per tablet, but retail pricing after insurance varies dramatically 15.

Clinical Considerations Affecting Coverage Decisions

BCBS medical policies for ED medications consider the underlying etiology. Coverage is most straightforward for organic ED causes: diabetes mellitus (affects 35-75% of diabetic men per ADA data) 16, post-prostatectomy ED, spinal cord injury, and medication-induced ED. Psychogenic ED alone may face additional documentation requirements.

Vardenafil carries specific cardiovascular safety data that may support coverage in patients with comorbid conditions. The key trials enrolled men with controlled hypertension, hyperlipidemia, and diabetes without increased cardiovascular event rates 1. The Princeton III Consensus guidelines recommend that PDE5 inhibitor use is safe in men at low cardiovascular risk and can be considered in intermediate-risk patients after cardiac evaluation 17.

Contraindications that would appropriately result in coverage denial include concurrent nitrate therapy (absolute contraindication due to profound hypotension risk), recent stroke or MI within 6 months, or unstable angina 18. BCBS utilization management programs may flag these combinations through pharmacy claims data and issue safety denials distinct from formulary-based denials.

Quantity Limits and Refill Restrictions

Most BCBS plans impose quantity limits of 6-12 vardenafil tablets per 30-day period. These limits derive from the FDA-labeled maximum of one dose per 24 hours and reflect insurer assumptions about expected sexual frequency. Some plans distinguish between initial fills (limited to 4-6 tablets for tolerability assessment) and maintenance fills (up to 8-12 tablets) 2.

Quantity limit exceptions require prescriber documentation of medical necessity for higher quantities. Clinical scenarios supporting exceptions include: younger patients in stable relationships with documented higher coital frequency, patients requiring lower per-dose efficacy who use the medication more frequently, or patients concurrently using vardenafil for off-label indications with supporting evidence. A systematic review of PDE5 inhibitor dosing patterns found that real-world usage often exceeds insurer-imposed limits 19.

Refill timing restrictions typically require 75-80% of the previous supply period to elapse before a new fill. Early refill requests are automatically rejected at the pharmacy unless a vacation override or lost medication exception is processed through your BCBS plan's pharmacy benefits manager.